CNBX Pharmaceuticals, Inc. (CNBX)
0.0001
0.00 (0.00%)
USD |
OTCM |
Sep 24, 16:00
CNBX Pharmaceuticals Research and Development Expense (Annual) : 0.00 for Aug. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| August 31, 2025 | 0.00 |
| August 31, 2024 | 0.1948M |
| August 31, 2023 | 0.4316M |
| August 31, 2022 | 1.183M |
| August 31, 2021 | 1.772M |
| August 31, 2020 | 1.682M |
| August 31, 2019 | 1.544M |
| August 31, 2018 | 1.004M |
| August 31, 2017 | 0.2469M |
| August 31, 2016 | 0.1776M |
| Date | Value |
|---|---|
| August 31, 2015 | 0.1394M |
| August 31, 2014 | 0.00 |
| August 31, 2013 | 0.00 |
| August 31, 2012 | 0.00 |
| August 31, 2011 | 0.00 |
| August 31, 2010 | 0.00 |
| August 31, 2009 | 0.00 |
| August 31, 2008 | 0.00 |
| August 31, 2007 | 0.00 |
| August 31, 2006 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Cocrystal Pharma, Inc. | 5.055M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 282.90M |
| Fulcrum Therapeutics, Inc. | 54.71M |
| Definium Therapeutics, Inc. | 117.66M |